Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
321-340 of 1,694 trials

Focal Segmental Glomerulosclerosis: DMX-200 Treatment Study

We are studying the effects of DMX-200 on kidney function in patients with focal segmental glomerulosclerosis who are taking an angiotensin II receptor blocker. This trial will help us understand its safety and effectiveness compared to standard treatments.

Focal Segmental Glomerulosclerosis>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteNephrology

Chronic Lymphocytic Leukemia: Venetoclax and Obinutuzumab Study

We are assessing the effectiveness and safety of a combination treatment for adults with recurring chronic lymphocytic leukemia. This study aims to understand how well the treatment works and what side effects may occur.

Recurrent Chronic Lymphocytic Leukemia1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Chemotherapy-Induced Peripheral Neuropathy: Capsaicin Patch vs. Duloxetine

We are studying whether a capsaicin patch can reduce nerve pain better than duloxetine in patients with chemotherapy-induced peripheral neuropathy. The trial also looks at safety and overall quality of life improvements.

Chemotherapy Induced Peripheral Neuropathy>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurologyOncology

Antithrombotic Therapy After Aortic Valve Implantation

We are studying whether a personalized, CT-guided antithrombotic therapy can better reduce serious heart and bleeding events compared to standard treatment in patients after transcatheter aortic valve implantation.

Aortic Valve StenosisMonitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Chronic Lymphocytic Leukemia: Zanubrutinib and Obinutuzumab Study

We are studying a combination of zanubrutinib and obinutuzumab for patients with untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. The trial aims to see if this treatment helps achieve better remission rates compared to different schedules of drug administration.

Chronic Lymphocytic Leukemia (CLL)3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Richter Transformation: Testing New Combination Therapy

We are studying a combination of three medications for patients with Richter transformation of chronic lymphocytic leukemia. The goal is to evaluate how well this treatment works and its safety.

Chronic Lymphocytic Leukaemia Variants>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Cholestatic Pruritus: Volixibat Study

We are testing a new drug, volixibat, for patients with itching caused by primary biliary cholangitis. The study aims to see if it can reduce itching and improve quality of life compared to a placebo.

Primary Biliary Cholangitis6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHepatologyInternal Medicine

Hydroxychloroquine for Pregnancy Outcomes in Women with Antiphospholipid Antibodies

We are studying whether hydroxychloroquine can improve pregnancy outcomes for women with antiphospholipid antibodies. This research aims to help understand its potential benefits during pregnancy.

Antiphospholipid Antibodies>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesGynecology and ObstetricsInternal Medicine

Vitamin D Deficiency: Cholecalciferol Study for Postmenopausal Women

We are investigating the right dose of Cholecalciferol to help postmenopausal women with vitamin D deficiency. The study also looks at how satisfied participants are with this vitamin D supplement.

Postmenopausal Women6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Anti-NMDA Receptor Encephalitis: Inebilizumab Study

We are testing a new treatment called inebilizumab for people with anti-NMDA receptor encephalitis. The study aims to see if it helps improve disability compared to a placebo.

Anti-NMDA Receptor Encephalitis1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineNeurology

Inotuzumab Ozogamicin for Pediatric Acute Lymphoblastic Leukemia

We are studying a new treatment for children with relapsed or refractory Acute Lymphoblastic Leukemia to see how well it works and how safe it is. This trial includes both single-agent and combination therapy approaches.

Recurrent Pediatric Acute Lymphoblastic LeukemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyPediatrics

Prostate Cancer: Estradiol and Exercise Study

We are exploring whether transdermal estradiol and resistance training can help reduce side effects like sexual dysfunction in men undergoing androgen deprivation therapy for prostate cancer. The study also looks at safety and quality of life improvements.

Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyUrology

Cytisine for Quitting Nicotine in E-Cigarettes and Tobacco

We are studying whether cytisine, combined with behavioral support, helps people quit using nicotine in e-cigarettes or tobacco cigarettes better than a placebo. This trial is for individuals motivated to stop using these products.

Quitting Electronic Cigarettes≤3 monthsConfirmation phase (III)Standard MedicinesPsychiatry

Atopic Dermatitis in Children: Upadacitinib vs. Dupilumab

We are studying whether upadacitinib is as safe and effective as dupilumab for children aged 2 to under 12 with moderate to severe atopic dermatitis. This trial aims to find better treatment options for young patients.

Atopic Dermatitis>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteAllergologyDermatologyPediatrics

Myelofibrosis: Navtemadlin with Ruxolitinib

We are studying whether adding navtemadlin to ruxolitinib helps patients with myelofibrosis who aren't responding well to their current treatment. The trial looks at changes in spleen size and symptoms, along with safety and survival.

MyelofibrosisPrimary MyelofibrosisSecondary Myelofibrosis>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematologyOncology

Insomnia in Psychiatric Patients: Melatonin vs. Quetiapine

We are studying whether melatonin or low-dose quetiapine can improve sleep and overall well-being in patients with psychiatric disorders and chronic insomnia. This trial compares these treatments to a placebo to find the most effective option.

Psychiatric Disorders and Insomnia>2 yearsEfficacy phase (II)Confirmation phase (III)Standard MedicinesPsychiatry

Bronchiectasis: Comparing Antibiotic Treatments for PA Infection

We are studying two antibiotic regimens to see which is more effective for adults with bronchiectasis and early Pseudomonas aeruginosa infections. This research may help improve treatment options for these patients.

Bronchiectasis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesPulmonology

Recurrent Pericarditis in Children: Anakinra vs. Steroids

We are studying whether Anakinra is more effective than steroids for controlling recurrent pericarditis in children who haven't responded to other treatments. This trial aims to help improve care for young patients facing this condition.

Pericarditis3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyRheumatology

Chronic Pouchitis in Children: Vedolizumab IV Study

We are testing the intravenous medication vedolizumab in children with active chronic pouchitis to see if it helps them achieve remission. The study will also look at how well the treatment is tolerated and its overall effectiveness.

Pouchitis1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Cystic Fibrosis: VX-522 Treatment Study

We are testing a new medication, VX-522, for adults with cystic fibrosis who do not respond to current treatments. The study will help us understand its safety and effectiveness compared to existing therapies.

Cystic Fibrosis6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPulmonology